← brief for 2026-08-10 · Slowing decline

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Key takeaways

A new trial is starting to test a drug called elecoglipron in adults who have type 2 diabetes and reduced kidney function. Everyone taking part is already on dapagliflozin, a standard kidney-protective drug. Half will add elecoglipron and half will add a placebo (a dummy pill). There are no results yet.

Who did this work

Run by AstraZeneca.
Sites: Research Site

Source

Trial registration · ClinicalTrials.gov — CKD recruiting · 2026-08-04
https://clinicaltrials.gov/study/NCT07662135